Australian Diabetes Society: Australian Type 2 Diabetes Glycaemic Management Algorithm

Australian Living Evidence Consortium: Australian Evidence-Based Clinical Guidelines for Diabetes

Department of Health and Aged Care algorithm on PBS-subsidised pharmacotherapy for T2DM

PBS update: What it means for your T2D patients

Dr Kean-Seng Lim discusses the recent dapagliflozin listing and how it may guide treatment conversations.

Optimising T2D care with SGLT2 inhibitors

Dr Ted Wu discusses clinical benefits, PBS access, and real-world use of SGLT2 inhibitors in type 2 diabetes management.

T2D Expanded Listing in CV Risk

Prof. Andrew Sindone discusses the importance of treating CV risk factors in T2D, breaking down survival estimates and intervention strategies.

Podcast: Expanded PBS Access for Dapagliflozin

Learn how recent PBS changes support earlier use of SGLT2 inhibitors in high-risk type 2 diabetes patients—beyond glycemic control.

Optimising Diabete Care, Navigating PBS Changes

Watch Dr. Ted Wu and Dr. Konrad Kangru as they delve into strategies for optimising type 2 diabetes management and explore the latest PBS updates.

Diabetes Dialogues Vol 1: Overarching Treatment Goals for T2D Management

Join Endocrinologist A/Prof Roger Chen and General Practitioner Professor Charlotte Hespe for a discussion about the goals they set for their patients with type 2 diabetes.
 

Diabetes Dialogues Vol 2: Health checks for patients with T2D

Join Endocrinologist A/Prof Roger Chen and General Practitioner Professor Charlotte Hespe for a discussion about the health checks they regularly complete for their patients with type 2 diabetes.

Diabetes Dialogues Vol 3: Managing T2D through collaboration between primary and specialist care

Join Endocrinologist A/Prof Roger Chen and General Practitioner Professor Charlotte Hespe for a discussion about how primary and specialty care can work together effectively in diabetes management for the best patient outcomes.

Diabetes Dialogues Vol 4: Holistic Goals in T2D

Join Endocrinologist A/Prof Roger Chen and General Practitioner Professor Charlotte Hespe for a discussion about how they consider the health of the patient beyond T2D and the management goals they set.

Impact of Early Intervention in a Type 2 Diabetic Patient with CKD

Professor Serge Jabbour explains why acting early to manage declining renal function in your T2D patients is important and the role you can play to deliver better health outcomes.

The Relevance of CKD to the Endocrinologist’s T2D Patient

Professor Serge Jabbour considers the importance of managing declining kidney function and treating beyond glycaemic control in patients with T2D.
 

Research Review: Efficacy and Safety of Dapagliflozin in Patients with CKD, HF, and T2D

DECLARE-TIMI 58 Clinical Paper Summary

DECLARE, DAPA-CKD and DAPA-HF: Clinical Trial Explainer

Professor Serge Jabbour discusses the breadth of evidence for dapagliflozin across the DECLARE, DAPA-CKD and DAPA-HF trials and its use in the management of T2D, CKD and HFrEF.

Key statics for T2D 2024